Response to Selective RET Inhibition With LOXO-292 in a Patient With RET Fusion-Positive Lung Cancer With Leptomeningeal Metastases

Benzer Materyaller

• Complete Response to Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET Fusion–Positive Breast Cancer
  Yazar:: Watanabe, Satomi, ve diğerleri
  Baskı/Yayın Bilgisi: (2021)
• Activity of the Highly Specific RET Inhibitor Selpercatinib (LOXO-292) in Pediatric Patients With Tumors Harboring RET Gene Alterations
  Yazar:: Ortiz, Michael V., ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases
  Yazar:: Andreev-Drakhlin, Alexander, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• SUN-LB75 The Anti-Tumor Activity of the Selective Ret Inhibitor Selpercatinib (LOXO-292) in Medullary Thyroid Cancer Is Independent of the Specific RET Mutation
  Yazar:: Cabanillas, Maria E, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma
  Yazar:: Dias-Santagata, Dora, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)